Latest News and Press Releases

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024Lantheus...

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD upon...

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric CancersThe Phase 1 First-In-Human study is designed to assess the...

Trading under ticker symbol RADXComplements existing US shareholders (currently holding 21% of Radiopharm)No associated capital raisingModest admin & financial compliance overheads SYDNEY, Nov. ...

Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19...

SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic...

SYDNEY, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic...

Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrinPancreatic ductal adenocarcinoma is primary indication due to high unmet needPotential...

SYDNEY, Australia, April 17, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and...

SYDNEY, Australia, March 28, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and...